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Abstract
Background: Integrating omics approaches and mathematical systems biology models is a 
challenge. In a recent paper, Wilmes et al. demonstrated a qualitative integration of omics data 
streams to gain a mechanistic understanding of cyclosporine A toxicity. One of the major conclusion 
of Wilmes et al. is that cyclosporine A strongly activates the nuclear factor (erythroid-derived 2)-
like 2 pathway (Nrf2) in renal proximal tubular epithelial cells exposed in vitro. We pursue here the 
analysis of those data with a quantitative integration of omics data with a differential equation 
model of the Nrf2 pathway. That was done in two steps: (i) Modeling the in vitro pharmacokinetics 
of cyclosporine A (exchange between cells, culture medium and vial walls) with a minimal 
distribution model. (ii) Modeling the time course of omics markers in response to cyclosporine A 
exposure at the cell level with a coupled PK-systems biology model. Posterior statistical 
distributions of the parameter values were obtained by Markov chain Monte Carlo sampling. 
Results: Data are well simulated, and the known in vitro toxic effect EC50 is well matched by 
model predictions. In vitro pharmacokinetic results bring out the presence of nonlinear phenomena 
in the distribution of cyclosporine A in the cell. At the same time, systems biology results bring out 
the presence of an important dose-dependent response. Conclusions: Our modeling and simulations 
of the CsA mediated ROS production gives biologists insight into mechanisms of toxicity and 
provide quantitative estimates of toxicity beyond the time and dose range used in experiments.
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Abbreviations
AhR: aryl hydrocarbon receptor (transcription factor protein)
ARE: antioxidant response element
ARNT: aryl hydrocarbon receptor nuclear translocator (protein)
CsA: cyclosporine A
CsAcytosol: Cystosol CsA quantity
CsAextracellular: Extracellular CsA quantity
CsAwall:  CsA on wall quantity
CYP: cytochrome P450 3A5
DRE: dioxin response element
GCL: glutamate cysteine ligase
GCLC: glutamate cysteine ligase catalytic subunit
GCLM: glutamate cysteine ligase modifier subunit
GPx: glutathione peroxidase
GS: glutathione synthetase
GSH: glutathione
GSSG: glutathione disulfide
Keap1: Kelch-like ECH-associated protein 1
MCMC: Markov chain Monte Carlo
mRNA: messenger ribonucleic acid
MRP: Multidrug resistance protein
MTX: metabolomic
Nrf2: nuclear factor (erythroid-derived 2)-like 2
NMA: complex of Nrf2-Maf-ARE
NRS: Non reactive species
PK: pharmacokinetics
PTX: proteomic
ROS: reactive oxygen species
RPTEC: renal proximal tubular epithelial cells
TCX: transcriptomic
XAA: complex of CsA-AhR-ARNT
XAAD: complex of CsA-AhR-ARNT-DRE
zmol: zeptomole (1 zmol = 10-21 mol)
γ-GC: γ-glutamylcysteine
Introduction
The quantitative modeling of toxicity pathways is a topic of current interest in predictive 
pharmacology and toxicology [2,3,4]. One of its challenges is to integrate omics data with systemic 
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biology models for parametric inference and model checking [5]. In a recent paper, Wilmes et al. 
[1] demonstrated a qualitative integration of transcriptomic (TCX), proteomic (PTX) and 
metabolomic (MTX) data streams to gain a mechanistic understanding of cyclosporine A (CsA) 
toxicity. CsA is an important molecule for immunosuppressive treatment and is used in many post-
graft medical protocols [6]. However, at high dose it is nephrotoxic, causing damage to the kidney 
vasculature, glomerulus and proximal tubule [7,8,9]. Yet, the precise mechanisms of its toxicity are 
still unclear: CsA is thought to induce oxidative stress at the mitochondrial level, and co-
administration of antioxidants with CsA appears to mitigate its nephrotoxic effects [10].
The Nrf2 oxidative response pathway is triggered when oxidative stress is sensed by Keap-1, 
resulting in stabilization and nuclear translocation of Nrf2 [11]. Nrf2 binds to the antioxidant 
response element (ARE) inducing the transcription of several genes involved in glutathione 
synthesis and recycling, antioxidant activity and phase II metabolism and transport [11]. The Nrf2 
response has been shown to induced in several tissues in response to chemical and physiological 
stressors. The kidney and particularly the proximal tubule is especially sensitive to oxidative stress 
and many nephrotoxins induce Nrf2 nuclear translocation and Nrf2 dependent gene induction in 
renal epithelial cells, including potassium bromate, cadmium chloride, diquat dibromide and 
cyclosporine A [1,12,13]. Moreover, we have recently shown physiological stress such as glucose 
depletion and subsequent re-introduction results in Nrf2 activation in renal cells [14]. Here, we 
pursue here the analysis of that data set with a quantitative integration of omics data with a systems 
biology model of the Nrf2 pathway. The model predictive ability is then assessed.
Methods
Data
RPTECs culture conditions, CsA concentrations measurements, and TCX, PTX and MTX 
data collection and analysis were described in detail in Wilmes et al. [1]. Briefly, RPTECs cells 
were cultured in serum-free medium and matured for two weeks on microporous supports. They 
were then treated for fourteen days with daily doses of CsA. The assay medium was renewed prior 
to each dosing. Three groups of assays were performed in triplicate: control, low CsA concentration 
(5 μM) and high CsA concentration (15 μM).
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CsA concentration was measured in the medium on the first day at 0.5h, 1h, 3h, 6h and 24h 
(just before changing the medium), on the third, fifth, seventh, and tenth day at 24h (before 
changing the medium), and on day fourteenth at the same times than on the day one. Intracellular 
(cell lysate) CsA concentration and quantity bound to plastic were measured on the first and last 
days at the same times. Samples for TCX (conducted with Illumina® HT 12 v3 BeadChip arrays), 
PTX (conducted with HPLC-MS) and MTX (conducted with direct infusion MS) measurements 
were obtained at the end of day 1, day 3 and day 14. All fold-changes were calculated using the 
absolute value measured at the first time of the control experiment as a reference, and for all doses. 
Typical RPTEC cell volume was determined by electron microscopy and stereology, to be 2000 ± 
140 µm3.
All the data used are given in Supplementary tables S1 to S8.
Mathematical model
Modeling was done into two steps: (i) Modeling the in vitro pharmacokinetics (PK) of CsA 
(exchange between cells, medium and vial walls) with a minimal distribution model. (ii) Modeling 
the effects of CsA on omics markers as the cellular level with a coupled PK-systems biology model. 
In vitro pharmacokinetic model. A 3-compartment model was developed to describe CsA 
exchange between cell medium, cells and vial walls [1]. In that model, CsA can enter and exit the 
cells, bind to and unbind from the plastic walls and can be metabolized within  cells. Several  
mathematical forms for exchange rates were tested. The best fit was obtained using a first order 
entry into cells with Michaelis-Menten (saturable) exit rate, a first order attachment to vial wall with 
non-integer (fractal) order detachment, and Michaelis-Menten metabolism. The following 
differential equations were used to describe the time course of CsA quantities in the cytosol, 
medium, and on vial walls:
∂CsA cytosol
∂ t
= CL in 1
CsA extracellular
V extracellular
−
CL out 1
⋅CsA cytosol
V cytosol ⋅Kmout 1
CsA cytosol
−
vmax⋅CsA cytosol
Km 2CsA cytosol (1)
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∂CsA extracellular
∂ t
= −CL in1
CsA extracellular
V extracellular

CL out 1
⋅CsA cytosol
V cytosol ⋅Km out 1
CsA cytosol
−k 1⋅CsA extracellular k2 CsA wall 
k3
(2)
∂CsA wall
∂ t
= k1⋅CsA extracellular −k2 CsA wall 
k 3
(3)
The model parameters are described in Table 1. 
Coupled PK-systems biology model of the Nrf2 pathways (Figure 1). The model used was 
adapted from Zhang et al. [15]. The model full set of equations is provided as supplemental 
material. In brief, CsA induces oxidative stress by increasing reactive oxygen species (ROS) 
production. ROS, owing to their electrophilicity, can be detected by the molecular sensor Kelch-like 
ECH-associated protein 1 (Keap1), which promotes the ubiquitination and eventual degradation of 
Nrf2 [16,17]. When Keap1 is oxidized, Nrf2 ubiquitination is lowered [17], making Nrf2 available 
to enter the nucleus. Once in the nucleus, Nrf2 binds to small Maf proteins to form Nrf2-Maf 
heterodimers [18]. Those can bind to antioxidant responses elements (ARE) in the promoter region 
of glutamate cysteine ligase catalytic subunit (GCLC), glutamate cysteine ligase modifier subunit 
(GCLM), glutathione synthetase (GS), glutathione peroxidase (GPx), and MRP genes, inducing 
their transcriptions [16,18]. GCLC, GCLM, and GS are involved in GSH synthesis. GPx detoxifies 
ROS, using GSH as a co-substrate. Zhang's model was developed for a generic xenobiotic, so the 
following structural changes were made to consistently describe the cell kinetics and mode of action 
of CsA:
– CsA can enter or exit the cell, and attach to or detach from the vial walls as in the in vitro 
PK model (eqs. A10, A11, A13). Inside the cell, CsA distribution to the nucleus is explicitly 
modeled (eq. A12);
– In the cell, CsA is metabolized by cytochrome P450 3A5 (CYP3A5) into a metabolite X′ 
(not followed and non-influent on the system). CsA is mainly metabolized by CYP3A 
isoforms [6], and in kidney cells only CYP3A5 is significantly expressed [19];
– Oxidative stress, characterized by the total quantity of oxidative compounds in the cell 
(ROS), was explicitly introduced in the model as a state variable (eq. A75);
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– The production of ROS depends on CsA concentration in the cell, and ROS are eliminated 
by GPx (eq. A75) in a non-reactive species pool (NRS) (not followed and non-influent on 
the system);
– Keap1 and the Nrf2-Keap1 complex are oxidized by ROS (eqs. A52, A53, A72, A73).
All the other equations are the same than in Zhang et al. [15]. In addition, some parameters 
had to be set to particular values for CsA: In the model, xenobiotics can bind to the AhR nuclear 
receptor. However, CsA is not a known AhR ligand, so its binding parameters (kb2 and kb5) were set 
to zero. Supplemental Table S9 gives the model parameters and the state variables initial values.
Calibration of the models
The in vitro PK model parameters were calibrated, using Bayesian inference [5,20], with data 
on the CsA quantities measured in the medium, cells, and on vial walls (Table S1 to S6). Non-
informative (vague) prior parameter distributions were used (see Table 1). The data likelihoods were 
assumed to follow a lognormal distribution around the model predictions, a standard assumption 
with such measurements. Measurement error geometric standard deviations were assumed to be 
specific to each of the three measurement types (different procedure were used for their obtention). 
They were assigned vague log-uniform prior distributions and were calibrated together with the 
other model parameters. A total of 11 parameters (8 kinetic parameters and  3 statistical ones) were 
calibrated. Posterior statistical distributions of the parameter values were obtained by Markov chain 
Monte Carlo (MCMC) sampling [5]. 
For the coupled PK-Nrf2 pathway model, the parameters directly controlling CsA kinetics 
were set to the joint posterior distribution mode found by the above calibration (see Table 1). 
Another set of 27 structural parameters (Table 2) was calibrated using fold-change omics data (as a 
function of time and CsA dose) on Nrf2 mRNA, CYP3A5 mRNA, GS mRNA, GCLC mRNA, 
GCLM mRNA, GST mRNA, GPx mRNA, MRP mRNA, GCLM protein, GS protein, MRP protein, 
γ-glutamylcysteine (γ-GC), and GSH. Four of those parameters have a direct influence on the rate 
of ROS synthesis, metabolism and interaction with Keap1. Another 15 parameters controle the 
activation and induction of Nrf2, GCLC, GCLM, GST, GPx, CYP3A5, GS and MRP genes 
transcription. Another six parameters controle synthesis and elimination of γ-GC and GSH, and  two 
last parameters controle CsA metabolism and Nrf2 and Maf binding. Model predicted fold-changes 
were computed the same way as the experimental ones, using the actual quantity predicted at the 
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first time of the control experiment as a reference. The prior parameter distributions chosen were 
either vague or centered around the values used by Zhang [15] (see Table 2). The data likelihoods 
were assumed to be lognormal distributions around the model predictions. The same measurement 
error geometric standard deviation was assumed for all omics measurements. It was calibrated 
together with the other model parameters, using a vague log-uniform prior. Here also, posterior 
distributions of the parameter values were obtained by MCMC sampling. For each model parameter 
sampled, convergence was evaluated by computing the potential scale reduction criterion of 
Gelman and Rubin [21] on the last 200,000 iterations from each simulated chain.
Software used
All model simulations and MCMC calibrations were performed with GNU MCSim v5.4.0 [5]. 
The R software, version 2.15.1 [22] was used for other statistical analyses and plots.
Results
Results for the in vitro pharmacokinetic model have been previously reported in Wilmes et al. 
[1] and are briefly summarized here. Overall, the data were well simulated. Exposure to low 
concentrations of CsA (5 µM) led to a dynamic steady state in about 3 days. The average ratio 
between extracellular and intracellular CsA concentrations was about 200, consistent with the fact 
that CsA is lipophilic and accumulates in cells. Exposure to high concentrations of CsA (15 µM) led 
to major alterations of the biodistribution of CsA over time. Steady state was reached in the cells 
only after approximately 7 days. The average ratio of intracellular to extracellular CsA 
concentrations was about 200 on the first day (like at low concentration) and around 650 on the last 
day. Those results highlight the presence of nonlinear phenomena in the distribution of CsA in 
RPTECs. Note here the importance of administering repeated doses: A unique administration would 
not have uncovered those phenomena. 
Figure 2 show the influence of the extra-cellular concentration of CsA on the evolution of 
intra-cellular CsA quantities over time. Those results confirm the presence of nonlinear phenomena 
in the distribution of CsA in the cell. Moreover, above about 15 µM extra-cellular CsA, intra-
cellular concentration do not reach a plateau within 14 days. This can be explained by the saturation 
of the cell efflux mechanism.
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Coupled PK-systems biology model of the Nrf2 pathway. All the analyses and predictions 
presented here were made using a (posterior) random sample of 5000 parameter vectors, obtained 
by thinning the 200,000 last iterations of five MCMC chains at convergence. Figures 3 and 4 show 
the model fit obtained for the in vitro omics data, at low and high CsA exposure dose, respectively. 
The bundle of curves presented reflect residual uncertainty in the model predictions, resulting from 
unavoidable measurement errors and modeling approximations. Overall the data is reasonably well 
simulated. For all species, the time profiles are clearly different between the two doses. At low CsA 
exposure (Figure 3) periodic oscillations are pervasive and after 14 days, the system does not appear 
to have reached a dynamic equilibrium. For many curves (corresponding to parameter vectors, 
including the most probable one), the oscillations are not stable. Their period may differ from one 
curve to another and go up to four days, even though the period of CsA administration is exactly 
one day. Supplemental Figure S1 extends the simulation period to 60 days, time at which a dynamic 
equilibrium is reached in all cases, and shows the same oscillation pattern. At the high CsA 
exposure (Figure 4) two patterns emerge:
The first type of profile, which concerns all species except GSH and γ-GC, is a plateauing 
curve. Different maximum values are reached after three days by different curves. The second 
profile type, which only concerns GSH and γ-GC, begins by oscillations which have not stabilized 
within 14 days. Supplemental Figure S2 extends the simulation period to 60 days and precises the 
behavior of GSH and γ-GC. The initial oscillations decrease gradually in the amplitude to 
completely disappear after about 30 days.
Figure 5 illustrates the evolution of free nuclear Nrf2 protein and cellular ROS quantities over 
14 days at low or high repeated CsA dosing. These are model predictions for two non-observed 
species. Additional simulations were performed up to 60 days and the trends were similar (data not 
shown).
As for the previous species for which we had data, large differences are seen between low and 
high dosing. At low CsA exposure a cyclic pattern is observed, which disappears at high exposure 
where the ROS quantity grows (less than exponentially) while the Nrf2 protein quantity reaches 
systematically a plateau.Figure 6 shows the influence of the extracellular CsA concentration on the 
evolution of cellular ROS, nuclear Nrf2 protein, cellular GSH and cellular GCL quantities over 
time. Figures for other species (GCLC, GCLM, GPx, GS and GST) are not shown because their 
profiles are very similar to the GCL one. Figure 6 shows that the extracellular concentration of CsA 
has a large influence on the amount of ROS in the cytosol. For extracellular CsA concentrations 
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below 8 µM CsA, the concentration (or quantity) vs. time profile of cytosolic ROS is oscillating, 
above 8 µM CsA, the ROS profile rises  in a hockey-stick fashion.
For nuclear Nrf2, cellular GSH and cellular GCL, depending on the extracellular CsA 
concentration, the model predicts either oscillating profiles or plateauing concentration vs. time 
profiles. As for ROS, the transition is rather abrupt and occurs approximately at 8 µM CsA.
Discussion
A proper assessment of drug or chemical safety from in vitro assays requires the measurement 
of concentration of the parent molecule and eventually its metabolites) in the assay medium and in 
cells [23,24]. Kinetic modeling can then be used to interpolate and extrapolate the data obtained. 
Here, an in vitro pharmacokinetic model was built using LC-MS/MS data on the distribution of CsA 
over time in human RPTECs. CsA is highly lipophilic and its rapid uptake and accumulation in cells 
was observed. At 5 µM CsA (daily initial extracellular concentration), the model indicated that 
steady-state was reached in about 2 days, whereas at 15 µM CsA, steady-state was reached only 
after 7 days. Moreover, cellular CsA concentrations at steady-state were clearly not proportional to 
exposure, and a disproportionate accumulation of CsA was observed at high exposure. Drug 
accumulation in target tissues is often associated with tissue-specific toxicities, and it is important 
to account for it. Such a bioaccumulation could be explained by the saturation of the P-glycoprotein 
efflux transporter (ABCB1) above 5 µM exposure [1]. We did not observe a modulation of CsA PK 
by its PD in our in vitro system, even though CsA interactions with transporters are known [25]. In 
particular, CYP 3A5 levels were not affected by CsA levels, so CsA metabolism was not disturbed 
by induction or repression.
Zhang's model was not intended to be used specifically with CsA or our cell system, so we 
had to re-calibrate several parameter values. This was done in a Bayesian statistical framework [20], 
to take into account the prior information we had on several parameters. The choice of parameters 
to be estimated was based on the results of a sensitivity analysis performed on all parameters in the 
model (results not shown). For most parameters, the posterior mean estimate was clearly different 
from the prior mean. Compared to Zhang's model, the parameters controlling ROS formation (kf75) 
and ROS elimination (vmax8b) stabilize at, respectively, higher and lower values after MCMC 
sampling. The ROS levels reached in Zhang's model are probably lower than in our cell system, so 
their formation was increased and their elimination decreased. We centered our GPx parameters’ 
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priors on the values used by Zhang et al. for GST. Since the observed GST and GPx omic data 
profiles were very different, it is not surprising that the posterior distributions of GPx parameters 
are clearly different from their prior. Through the Nrf2 pathway, CsA seems to have an important 
influence on GCLC and GCLM synthesis. While the basal transcription rates of GCLC and GCLM 
stabilize at values close to those of Zhang's et al., parameters of GCLC and GCLM genes regulation 
by NMAs, linked to ROS and CsA levels, stabilize at values about four times higher.
The model gives access to unmeasured effects of CsA to cells, closer to a toxicity endpoint. 
The generation of ROS by CsA is an important toxicity mechanism for that molecule. The retro-
control of ROS scavenging by ROS themselves, through the Nrf2 signaling pathway, induces a 
highly nonlinear behavior illustrated on Figure 6. ROS generation runs out of control at CsA 
exposure levels close to the high dose assayed in vitro (15 µM for extra-cellular concentration). We 
have an external validation of this finding. The 15 µM concentration was experimentally chosen to 
be the highest not affecting cell survival. We know that above that level, toxicity would start to have 
an impact on survival, so our model predictions seem reasonable. However, as in many systems 
biology models, only one signaling pathway has been taken into account in our model. Other ROS 
scavenging mechanisms are present in RPTECs and could be involved. On the other hand, CsA 
nephrotoxicity involves several mechanism [26 ,27 ,28 ,29 ,30] and it is possible that ROS 
generation is not enough to cause critical damages.
Conclusion
Integrating omics approaches with mathematical systems biology models is still rarely done 
[31,32], even though that seems the best way to both understand the data and improve the predictive 
ability of the models [33 ,34]. Our modeling and simulations of the CsA mediated ROS production 
gives biologists insight into mechanisms of toxicity and provide quantitative estimates of toxicity 
beyond the time and dose range used in experiments. To go further, it would be interesting to have a 
more precise model description of GSH synthesis in the model, since cellular ROS concentrations 
are clearly correlated to GSH. It would also be interesting to couple this model with a physiological 
based pharmacokinetic (PBPK) model for CsA to be able to better predict human response.
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Tables
Table 1: In vitro CsA kinetic parameters description and their statistical distributions.
Parameter Description Units Prior Posterior mode,mean ± SD
CL in 1
Diffusion rate constant for 
cellular uptake µm
3.sec-1 LU*(10-1, 104) 99.6,99.8 ± 21
Kmout 1
Michaelis constant for 
diffusion for cellular efflux zmol.µm
-3 LU(100, 50000) 2965,3160 ± 620
CL out 1
Km out 1
Diffusion rate constant 
over Michaelis constant for 
cellular efflux
µm3.sec-1 LU(10-2, 20) 0.581,0.568 ± 0.16
k1
Plastic binding rate 
constant sec
-1 LU(10-6, 5×10-4) 3.55×10
-5,
3.54×10-5 ± 1.0×10-5
k3
Power law coefficient for 
unbinding dimensionless Uniform(0, 0.95)
0.921,
0.802 ± 0.074
k2
Plastic unbinding rate 
constant zmol
(1-k3)**.sec-1 LU(10-4, 0.5) 6.01×10
-4,
6.09×10-3 ± 8.7×10-3
vmax
Maximum rate of 
metabolism zmol.sec
-1 LU(0.1, 5000) 40.0,47.2 ± 14
Km2
Michaelis constant for 
intra-cellular metabolism zmol LU(5
×105, 5×107) 2.18×10
6,
3.43×106 ± 2.2×106
**: LU: Log-uniform distribution (lower bound, upper bound).
*: 1 zmol = 1 zeptomole = 10-21 mol
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Table 2: Systems biology model parameters description and their statistical distributions.
Parameter Description Units Prior distribution Posterior mode,mean ± SD
vmax 7
Maximum rate of CsA 
metabolism sec
-1 LN(0.2, 3) 0.1870.274 ± 0.233
k f 75
Basal rate of ROS 
formation zmol.sec
-1 LN(12, 3) 79.1135 ± 80.8
vmax 8b
Maximum rate of ROS 
metabolism sec
-1 LN(8, 3) 2.673.88 ± 2.54
kox 10
Keap1 oxidation rate 
constant zmol
-1.sec-1 Uniform(10-8, 10-2) 3.02×10
-6
3.86×10-6 ± 2.72×10-6
kROS
ROS formation rate 
constant sec
-1 Uniform(10-8, 10-2) 6.55×10
-5
8.86×10-6 ± 3.86×10-5
kb18
Nrf2 and Maf binding 
rate constant sec
-1 LN(0.003, 3) 0.01240.0193 ± 0.0167
kTSP 21
mRNACYP transcription 
rate constant sec
-1 LN(1.07, 3) 1.291.65 ± 1.85
kTSP28
mRNANrf2 transcription 
rate constant sec
-1 LN(0.00611, 3) 0.0870.062 ± 0.0603
kTSP34
mRNAGS transcription 
rate constant sec
-1 LN(1.15, 3) 1.071.34 ± 0.53
kTSP42
mRNAGCLC transcription 
rate constant sec
-1 LN(1.98, 3) 1.282.27 ± 1.91
kTSP48
mRNAGCLM transcription 
rateconstant sec
-1 LN(3.22, 3) 3.954.84 ± 3.79
kTSP57
mRNAGST transcription 
rate constant sec
-1 LN(0.242, 3) 0.0210.553 ± 0.949
kTSP57b
mRNAGPx transcription 
rate constant sec
-1 LN(0.242, 3) 0.0980.123 ± 0.0779
kTSP66
mRNAMRP transcription 
rate constant sec
-1 LN(0.9, 3) 1.222.23 ± 3.55
kb52
GCLC and GCLM 
binding rate constant sec
-1 LN(2×10-5, 3) 4.33×10
-6
1.09×10-5 ± 9.19×10-6
*: 1 zmol = 1 zeptomole = 10-21 mol
**: LN: Log-normal distribution (mean, SD).
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Table 2 (followed): Systems biology model parameters description and their statistical distributions.
Parameter Description Posterior mode,mean ± SD Prior distribution
Posterior mode,
mean ± SD
kind(NMA)27
Induction coefficient for Nrf2 
gene zmol
-1.sec-1 LN(100, 3) 150236 ± 433
kind(NMA)33
Induction coefficient for GS 
gene zmol
-1.sec-1 LN(5.95, 3) 2.173.85 ± 2.33
kind(NMA)41
Induction coefficient for 
GCLC gene zmol
-1.sec-1 LN(8.7, 3) 22.143.2 ± 25
kind(NMA)47
Induction coefficient for 
GCLM gene zmol
-1.sec-1 LN(1.6, 3) 3.285.75 ± 3.15
kind(NMA)56
Induction coefficient for GST 
gene zmol
-1.sec-1 LN(11.9, 3) 8.4610.4 ± 8.61
kind(NMA)56b
Induction coefficient for GPx 
gene zmol
-1.sec-1 LN(11.9, 3) 1.376.75 ± 6.51
kind(NMA)65
Induction coefficient for 
MRP gene zmol
-1.sec-1 LN(16, 3) 6.439.62 ± 7.85
vmax(GCL)72
Maximum rate of γ-GC 
synthesis sec
-1 LN(8.2, 3) 83.480.3 ± 67.5
vmax(GCLC)72
Maximum rate of γ-GC 
synthesis sec
-1 LN(1.9, 3) 1.642.16 ± 3.11
vmax73
Maximum rate of GSH 
synthesis sec
-1 LN(6.5, 3) 8.5710.3 ± 4.43
vmax74
Maximum rate of GSH 
degradation zmol.sec
-1 LN(1845, 3) 283374 ± 353
Km74
Michaelis-Menten constant of 
GSH degradation zmol LN(2×10
7, 3) 1.62×10
8
2.22×108 ± 2.36×108
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Figure 1: Schematic representation of the coupled PK biology systems model of the Nrf2 pathways.
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Figure 2: Predictions of intracellular CsA quantity (versus time and CsA administered). Thick red 
lines are predictions for 5 µM and 15 µM.
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Figure 3: Omics fold-changes time-course in RPTEC cell with repeated low dose (5 µM) of CsA. 
Transcriptomics (Nrf2 mRNA, GS mRNA, GCLC mRNA, GCLM mRNA, GST mRNA, GPx 
mRNA and MRP mRNA) proteomics (GCLM, GS, and MRP), and metabolomics (γ-GC, and GSH) 
fold-changes time-course in RPTEC cells during 14 days with repeated low dose (5 µM) of CsA. 
The blue line indicates the best fitting (maximum posterior probability) model prediction. The black 
lines are predictions made with 49 random parameter sets. Red circles indicate data.
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Figure 4: Omics fold-changes time-course in RPTEC cell with repeated high dose (15 µM) of CsA. 
Transcriptomics (Nrf2 mRNA, GS mRNA, GCLC mRNA, GCLM mRNA, GST mRNA, GPx 
mRNA and MRP mRNA) proteomics (GCLM, GS, and MRP), and metabolomics (γ-GC, and GSH) 
fold-changes time-course in RPTEC cells during 14 days with repeated high dose (15 µM) of CsA. 
The blue line indicates the best fitting (maximum posterior probability) model prediction. The black 
lines are predictions made with 49 random parameter sets. Red circles indicate data.
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Figure 5: Pharmacokinetic modeling of cellular ROS and nuclear Nrf2 quantities. Pharmacokinetic 
modeling of cellular ROS quantity in cytosol for 5 µM (A1) and 15 µM (A2) and nuclear Nrf2 
quantity for 5 µM (B1) and 15 µM (B2), during 14 days. The blue line indicates the best fitting 
(maximum posterior probability) model prediction. The black lines (normal scales) and red lines 
(semi-logarithmic scales) are predictions made with 49 random parameter sets.
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Figure 6: Predictions of cellular ROS, nuclear Nrf2, cellular GSH and cellular GCL quantities. 
Predictions of cellular ROS (top left), nuclear Nrf2 (top right), cellular GSH (down left) and cellular 
GCL (down right) quantities (versus time and dose). Thick red lines are predictions for 5 µM and 15 
µM.
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Supplementary Material 
Differential equations of the Nrf2 model.
Table S1: Model parameters values and initial state variables values.
Table S2: CsA quantities measured in the extracellular medium (3mL) at low CsA concentration 
exposure (5 μM).
Table S3: Cellular CsA quantities measured at low CsA concentration exposure (5 μM).
Table S4: CsA quantities measured on plastic at low CsA concentration exposure (5 μM).
Table S5: CsA quantities measured in the extracellular medium (3mL) at high CsA concentration 
exposure (15 μM).
Table S6: Cellular CsA quantities measured at high CsA concentration exposure (15 μM).
Table S7: CsA quantities measured on plastic at high CsA concentration exposure (15 μM).
Table S8: Fold changes measured at low CsA concentration (5 μM).
Table S9: Fold changes measured at high CsA concentration (15 μM).
Figure S1: Transcriptomics (Nrf2 mRNA, CYP mRNA, GS mRNA, GCLC mRNA, GCLM 
mRNA, GPx mRNA, and MRP mRNA) proteomics (GCLM, GS, and MRP), and metabolomics (γ- 
GC, and GSH) fold-changes time-course in RPTEC cells during 60 days with repeated low dose (5 
μM) CsA dosing. The blue line indicates the best fitting (maximum posterior probability) model 
prediction. The black lines are predictions made with 49 random parameter sets.
Figure S2: Transcriptomics (Nrf2 mRNA, CYP mRNA, GS mRNA, GCLC mRNA, GCLM 
mRNA, GPx mRNA, and MRP mRNA) proteomics (GCLM, GS, and MRP), and metabolomics (γ- 
GC, and GSH) fold-changes time-course in RPTEC cells during 60 days with repeated high dose 
(15 μM) CsA dosing. The blue line indicates the best fitting (maximum posterior probability) model 
prediction. The black lines are predictions made with 49 random parameter sets.
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SUPPLEMENTARY MATERIAL
Differential equations of the Nrf2 model:
∂ AhRcytosol
∂ t
= −kb2
.CsAcytosol . AhRcytosolk u2
. CsA_AhRcytosol (A1)
∂ AhRnucleus
∂ t
= −k b5
.CsAnucleus . AhRnucleusku5
.CsA_AhRnucleus (A2)
∂ AREGCLC
∂ t = −kb40
. AREGCLC  Nrf2_MAF nucleus 
n40k u40
. NMAGCLC
(A3)
∂ AREGCLM
∂ t = −kb46
. AREGCLM Nrf2_MAF nucleus 
n46ku46
. NMAGCLM
(A4)
∂ AREGS
∂ t = −kb32
. AREGS Nrf2_MAF nucleus 
n32ku32
. NMAGS
(A5)
∂ AREGST
∂ t −k b54
. AREGST Nrf2_MAF nucleus 
n54ku54
. NMAGST
(A6)
∂ AREGPx
∂ t −k b54b
. AREGPx Nrf2_MAF nucleus 
n54bku54b
. NMAGPx
(A7)
∂ AREMRP
∂ t
= −kb63
. ARE MRP Nrf2_MAF nucleus 
n63ku63
. NMAMRP
(A8)
∂ ARE Nrf2
∂ t
= −k b25
. ARE Nrf2 Nrf2_MAF nucleus 
n25ku25
. NMANrf2
(A9)
∂ ARNT nucleus
∂ t
= −kb6
.CsA_AhRnucleus . ARNT nucleusku6
. XAAnucleus
(A10)
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∂CsAcytosol
∂ t
= CLin1
.
CsAextracellular
V extracellular
−
CLout 1
Kmout1
.
CsAcytosol
V cytosol
1
CsAcytosol
V cytosol . Kmout 1
−
vmax7
. CYPcytosol .CsAcytosol
Km2CsAcytosol
−kb2
. CsAcytosol . AhRcytosolku2
.CsA_AhRcytosol
−CLin4
.
CsAcytosol
V cytosol
CLout4
.
CsAnucleus
V nucleus
(A11)
∂CsAextracellular
∂ t = −CLin1
.
CsAextracellular
V extracellular

CLout1
Kmout 1
.
CsAcytosol
V cytosol
1
CsAcytosol
V cytosol . Kmout1
−k1 .CsAextracellulark2 CsAwall 
k3
(A12)
∂CsAnucleus
∂ t
= −kb5
. CsAnucleus . AhRnucleusku5
.CsA_AhRnucleus
CLin4
.
CsAcytosol
V cytosol
−CLout 4
.
CsAnucleus
V nucleus
(A13)
∂CsAwall
∂ t = k1 . CsAextracellular−k 2 CsAwall 
k3 (A14)
∂CsA_AhRcytosol
∂ t = kb2
.CsAcytosol . AhRcytosol−ku2
.CsA_AhRcytosol
−CLin3
.
CsA_AhRcytosol
V cytosol
CLout3
.
CsA_AhRnucleus
V nucleus
(A15)
∂CsA_AhRnucleus
∂ t
= CLin3
.
CsA_AhRcytosol
V cytosol
−CLout 3
.
CsA_AhRnucleus
V nucleus
kb5
.CsAnucleus . AhRnucleus−ku5
. CsA_AhRnucleus
−kb6
. CsA_AhRnucleus . ARNT nucleusku6
. XAAnucleus
(A16)
∂CYP cytosol
∂ t = −kdeg 24
.CYPcytosolkTSL23
. mRNACYP
(A17)
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∂ DRECYP
∂ t = −kb19
. DRECYP  XAAnucleus 
n19ku19
. XAADCYP
(A18)
∂ DREGST
∂ t = −kb55
. DREGST XAAnucleus 
n55ku55
. XAADGST
(A19)
∂ DREMRP
∂ t = −kb64
. DRE MRP  XAAnucleus 
n64ku64
. XAADMRP
(A20)
∂ DRE Nrf2
∂ t = −kb26
. DRE Nrf2  XAAnucleus 
n26ku26
. XAADNrf2
(A21)
∂GCLcytosol
∂ t
= kb52
. GCLCcytosol . GCLM cytosol−ku52
. GCLcytosol
−k deg53
.GCLcytosol
(A22)
∂GCLCcytosol
∂ t
= −k b52
.GCLCcytosol .GCLM cytosolk u52
. GCLcytosol
−k deg45
. GCLCcytosolkTSL44
. mRNAGCLC
(A23)
∂GCLM cytosol
∂ t
= −kb52
. GCLCcytosol . GCLM cytosolku52
. GCLcytosol
−k deg51
.GCLM cytosolkTSL50
. mRNAGCLM
(A24)
∂GeneCYPOFF
∂ t
= −k act20
.GeneCYPOFF
−k ind 20
.GeneCYPOFF
. XAADCYP
k desact20
.GeneCYPON
(A25)
∂GeneCYPON
∂ t
= kact 20
. GeneCYPOFF
k ind 20
. GeneCYPOFF
. XAADCYP
−kdesact 20
.GeneCYPON
(A25)
∂GeneGCLC OFF
∂ t
= −k act41
.GeneGCLC OFF
−k ind 41
.GeneGCLC OFF
. NMAGCLC
k desact41
.GeneGCCLON
(A27)
GeneGCLC ON
∂ t
= kact 41
. GeneGCLCOFF
k ind 41
. GeneGCLCOFF
. NMAGCLC
−k desact41
.GeneGCLC ON
(A28)
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∂GeneGCLM OFF
∂ t = −k act47
.GeneGCLM OFF
−k ind 47
.GeneGCLM OFF
. NMAGCLM
k desact47
.GeneGCLC ON
(A29)
∂GeneGCLM ON
∂ t
= kact 47
.GeneGCLM OFF
kind 47
.GeneGCLM OFF
. NMAGCLM
−kdesact47
.GeneGCLM ON
(A30)
∂GeneGS OFF
∂ t
= −k act33
.GeneGS OFF
−kind 33
.GeneGS OFF
. NMAGS
k desact33
.GeneGSON
(A31)
∂GeneGS ON
∂ t
= kact 33
.GeneGS OFF
k ind 33
.GeneGS OFF
. NMAGS
−k desact33
.GeneGS ON
(A32)
GeneGST OFF
∂ t
= −kact 56
.GeneGST OFF
−k ind(NMA)56
. GeneGST OFF
. NMAGST
−k ind(XAAD)56
.GeneGST OFF
. XAADGSTk desact56
.GeneGST ON
(A33)
GeneGST ON
∂ t
= k act56
. GeneGST OFF
k ind(NMA)56
.GeneGST OFF
. NMAGST
k ind(XAAD)56
. GeneGST OFF
. XAADGST−kdesact56
. GeneGST ON
(A34)
GeneGPxOFF
∂ t
= −k act56b
.GeneGPxOFF
−k ind(NMA)56b
.GeneGPxOFF
. NMAGPx
k desact56b
.GeneGPxON
(A35)
GeneGPxON
∂ t
= kact56b
.GeneGPxOFF
k ind(NMA)56b
.GeneGPxOFF
. NMAGPx
−kdesact 56b
.GeneGPxON
(A36)
     
∂GeneMRPOFF
∂ t
= −k act65
.GeneMRPOFF
−kind(NMA)65
.GeneMRPOFF
. NMAMRP
−k ind(XAAD)65
.GeneMRPOFF
. XAADMRPkdesact65
. GeneMRPON
 (A37)
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∂GeneMRPON
∂ t
= kact 65
.GeneMRPOFF
k ind(NMA)65
. GeneMRPOFF
. NMAMRP
k ind(XAAD)65
. GeneMRPOFF
. XAADMRP−kdesact 65
.GeneMRPON
 (A38)
∂GeneNrf2OFF
∂ t
= −kact 27
. GeneNrf2OFF
−k ind(NMA)27
.Gene Nrf2OFF
. NMANrf2
−k ind(XAAD)27
.Gene Nrf2OFF
. XAADNrf2kdesact27
. GeneNrf2ON
(A39)
∂GeneNrf2ON
∂ t
= kact 27
.GeneNrf2OFF
k ind(NMA)27
. GeneNrf2OFF
. NMANrf2
k ind(XAAD)27
.GeneNrf2OFF
. XAADNrf2−kdesact27
. GeneNrf2ON
(A40)
∂GS cytosol
∂ t = kb38
. GS monocytosol . GS monocytosol−ku38
.GScytosol
−k deg39
. GScytosol
(A41)
∂GS monocytosol
∂ t = −2. kb38
. GS monocytosol . GS monocytosol2.ku38
. GScytosol
−k deg37
.GS monocytosolkTSL36
. mRNAGS
(A42)
R11 =
ATPcytosol
K m(ATP)(GCL)721GSH cytosolK is(ATP)(GCL)72 ATPcytosol 1
GSH cytosol
K ii(ATP)(GCL)72 
(A43)
R12 =
Glu cytosol
K m(Glu)(GCL)72 1 GSH cytosolK is(Glu)(GCL)72 Glu cytosol1
GSH cytosol
K ii(Glu)(GCL)72 
(A44)
R13 =
vmax(GCL)72
.GCLcytosol .Cyscytosol
K m(Cys)(GCL)72
Cyscytosol
(A45)
R21 =
ATPcytosol
Km(ATP)(GCLC)72 1GSH cytosolK is(ATP)(GCLC)72 ATPcytosol 1
GSH cytosol
K ii(ATP)(GCLC)72 
(A46)
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R22 =
Glu cytosol
Km(Glu)(GCLC)72 1 GSH cytosolK is(Glu)(GCLC)72 Glucytosol1
GSH cytosol
K ii(Glu)(GCLC)72 
(A46)
R23 =
vmax(GCLC)72
.GCLC cytosol .Cyscytosol
Km(Cys)(GCLC)72
Cyscytosol
(A48)
R31 =
γGC cytosol
K m1(γGC)73

γGCcytosol
2
K m1(γGC)73
. Km2(γGC)73
1 +
2.γGCcytosol
Km1(γGC)73

γGCcytosol
2
K m1(γGC)73
. K m2(γGC)73
(A49)
R32 =
vmax73
.GS cytosol .Gly cytosol . ATPcytosol
K m(Gly)73Glycytosol  Km(ATP)73ATPcytosol 
(A50)
∂ γGC cytosol
∂ t = R11×R12×R13R21×R22×R23−R31×R32
(A51)
∂GSH cytosol
∂ t
= −
vmax74
.GSH cytosol
K m74
GSH cytosol
R31×R32
−
vmax8b
.GPxcytosol .GSH cytosol
K m(GSH)8b
GSH cytosol
.
ROS cytosol
Km(ROS)8b
ROScytosol
 (A52)
∂GST cytosol
∂ t = kb61
. GST monocytosol .GST monocytosol−ku61
.GST cytosol
−k deg62
. GST cytosol
(A53)
∂GST monocytosol
∂ t
= −2. kb61
.GST monocytosol .GST monocytosol2.ku61
.GST cytosol
−kdeg60
.GST monocytosolkTSL59
. mRNAGST
(A54)
∂ Keap1cytosol
∂ t = k red 10
. Keap1ocytosol−kox10
. Keap1cytosol . ROS cytosol
ku14
. Nrf2_Keap1cytosol−kb14
. Nrf2cytosol . Keap1cytosol
ku12
. Nrf2_Keap1cytosol
(A55)
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∂ Keap1ocytosol
∂ t = −k red10
. Keap1ocytosolkox10
. Keap1cytosol . ROS cytosol
ku15
. Nrf2_Keap1ocytosol−k b15
. Nrf2cytosol . Keap1ocytosol
ku13
. Nrf2_Keap1ocytosol
(A56)
∂mRNACYP
∂ t = −k deg22
.mRNACYPkTSP21
.GeneCYPON
(A57)
∂mRNAGCLC
∂ t
= −k deg43
. mRNAGCLCkTSP42
.GeneGCLC ON
(A58)
∂mRNAGCLM
∂ t
= −k deg49
. mRNAGCLMkTSP48
. GeneGCLM ON
(A59)
∂mRNAGS
∂ t = −kdeg35
. mRNAGSkTSP34
.GeneGS ON
(A60)
∂mRNAGST
∂ t = −kdeg58
. mRNAGSTkTSP57
.GeneGST ON
(A61)
∂mRNAGPx
∂ t
= −k deg58b
. mRNAGPxkTSP57b
.GeneGPxON
(A62)
∂mRNAMRP
∂ t
= −kdeg67
. mRNAMRPkTSP66
. GeneMRPON
(A63)
∂mRNANrf2
∂ t = −kdeg 29
. mRNANrf2kTSP28
.GeneNrf2ON
(A64)
∂MRPcytosol
∂ t = kb70
. MRP monocytosol . MRP monocytosol−ku70
. MRPcytosol
−kdeg71
. MRPcytosol
(A65)
∂MRP monocytosol
∂ t
= −2. kb70
. MRP monocytosol . MRP monocytosol2.ku70
. MRPcytosol
−kdeg69
. MRP monocytosolkTSL68
. mRNAMRP
(A66)
∂MAF nucleus
∂ t = −k b18
. MAF nucleus . Nrf2nucleusku18
. Nrf2_MAF nucleus
(A67)
∂ NMAGCLC
∂ t = kb40
. AREGCLC Nrf2_MAF nucleus 
n40−ku40
. NMAGCLC
(A68)
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∂ NMAGCLM
∂ t = kb46
. AREGCLM Nrf2_MAF nucleus 
n46−ku46
. NMAGCLM
(A69)
∂ NMAGS
∂ t = kb32
. AREGS Nrf2_MAF nucleus 
n32−ku32
. NMAGS
(A70)
∂ NMAGST
∂ t = k b54
. AREGST  Nrf2_MAF nucleus
n54−ku54
. NMAGST
(A71)
∂ NMAGPx
∂ t = kb54b
. AREGPx  Nrf2_MAF nucleus 
n54b−ku54b
. NMAGPx
(A72)
∂ NMAMRP
∂ t = kb63
. AREMRP Nrf2_MAF nucleus 
n63−ku63
. NMAMRP
(A73)
∂ NMANrf2
∂ t = kb25
. ARE Nrf2 Nrf2_MAF nucleus 
n25−k u25
. NMANrf2
(A74)
∂ Nrf2cytosol
∂ t = −k deg31
. Nrf2cytosolkTSL30
. mRNANrf2
−k b15
. Nrf2cytosol . Keap1ocytosolku15
. Nrf2_Keap1ocytosol
−k b14
. Nrf2cytosol . Keap1cytosolk u14
. Nrf2_Keap1cytosol
−CLin16
.
Nrf2cytosol
V cytosol
CLout16
.
Nrf2nucleus
V nucleus
(A75)
∂ Nrf2nucleus
∂ t
= −kb18
. Nrf2nucleus . Maf nucleusku18
. Nrf2_Maf nucleus
CLin16
.
Nrf2cytosol
V cytosol
−CLout 16
.
Nrf2nucleus
V nucleus
−kdeg17
. Nrf2nucleus
(A76)
∂ Nrf2_Keap1cytosol
∂ t = k red11
. Nrf2_Keap1ocytosol
−kox11
. Nrf2_Keap1cytosol . ROScytosol
−ku14
. Nrf2_Keap1cytosol
kb14
. Nrf2cytosol . Keap1cytosol
−ku12
. Nrf2_Keap1cytosol
(A77)
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∂ Nrf2_Keap1ocytosol
∂ t
= −k red11
. Nrf2_Keap1ocytosol
kox11
. Nrf2_Keap1cytosol . ROS cytosol
−ku15
. Nrf2_Keap1ocytosol
kb15
. Nrf2cytosol . Keap1ocytosol
−ku13
. Nrf2_Keap1ocytosol
(A78)
∂ Nrf2_Maf nucleus
∂ t
= −2. kb54
. AREGST Nrf2_MAF nucleus 
n542. ku54
. NMAGST
−2. kb54b
. AREGPx  Nrf2_MAF nucleus
n54b2. ku54b
. NMAGPx
−3. k b46
. AREGCLM Nrf2_MAF nucleus 
n463. ku46
. NMAGCLM
−kb25
. ARE Nrf2 Nrf2_MAF nucleus 
n25ku25
. NMANrf2
−2. kb63
. ARE MRP . Nrf2_MAF nucleus 
n632. ku63
. NMAMRP
−3. k b40
. AREGCLC  Nrf2_MAF nucleus
n403. ku40
. NMAGCLC
−2. kb32
. AREGS Nrf2_MAF nucleus 
n322. k u32
. NMAGS
kb18
. Nrf2nucleus . MAF nucleus−ku18
. Nrf2_MAF nuleus
(A79)
∂ ROS cytosol
∂ t
= k f 75
k ROS .CsAcytosol
−
vmax8b
. GPxcytosol .GSH cytosol
Km(GSH)8b
GSH cytosol
.
ROS cytosol
K m(ROS)8b
ROS cytosol
 (A80)
∂ XAAnucleus
∂ t = −2. k b26
. DRE Nrf2 XAAnucleus 
n262. ku26
. XAADNrf2
−2. k b19
. DRECYP  XAAnucleus 
n192. ku19
. XAADCYP
−2. k b55
. DREGST  XAAnucleus 
n552. ku55
. XAADGST
−k b64
. DREMRP  XAAnucleus
n64ku64
. XAADMRP
k b6
. X_AhRnucleus . ARNT nucleus−ku6
. XAAnucleus
(A81)
∂ XAADCYP
∂ t = kb19
. DRECYP  XAAnucleus 
n19−ku19
. XAADCYP
(A82)
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∂ XAADGST
∂ t = kb55
. DREGST  XAAnucleus
n55−ku55
. XAADGST
(A83)
∂ XAADMRP
∂ t = k b64
. DREMRP  XAAnucleus
n64−ku64
. XAADMRP
(A84)
∂ XAADNrf2
∂ t = kb26
. DRE Nrf2  XAAnucleus 
n26−ku26
. XAAD Nrf2
(A85)
32 / 45
Table S1: Model parameters values and initial state variables values.
Equation Parameters and initial state variables
A1:
∂ AhRcytosol
∂ t
AhRcytosol(initial) = 34 zmol
kb2 = 0 zmol
-1.s-1 ku2 = 0.02 s
-1
A2:
∂ AhRnucleus
∂ t
AhRnucleus(initial) = 0 zmol
kb5 = 0 zmol
-1.s-1 ku5 = 0.02 s
-1
A3:
∂ AREGCLC
∂ t
kb40 = 14.6 zmol-3.s-1 ku40 = 0.02 s
-1 n40 = 3
AREGCLC (initial) = 6.35E
-4 zmol
A4:
∂ AREGCLM
∂ t
kb46 = 14.6 zmol-3.s-1
ku46 = 0.02 s
-1 n46 = 3
AREGCLM (initial) = 6.35.E
-4 zmol
A5:
∂ AREGS
∂ t
kb32 = 0.29 zmol
-2.s-1 ku32 = 0.02 s
-1 n32 = 2
AREGS (initial) = 6.35E
-4 zmol
A6:
∂ AREGST
∂ t
kb54 = 0.29 zmol
-2.s-1 ku54 = 0.02 s
-1 n54 = 2
AREGST (initial) = 6.35E
-4 zmol
A7:
∂ AREGPx
∂ t
kb54b = 0.29 zmol
-2.s-1 ku54b = 0.02 s
-1 n54b = 2
AREGPx (initial) = 6.35E
-4 zmol
A8:
∂ AREMRP
∂ t
kb63 = 0.29 zmol
-2.s-1 ku63 = 0.02 s
-1 n63 = 2
AREMRP (initial) = 6.35E
-4 zmol
A9:
∂ ARE Nrf2
∂ t
kb25 = 5.26E
-3 zmol-1.s-1 ku25 = 0.02 s
-1 n25 = 1
ARE Nrf2(initial) = 6.35E
-3 zmol
A10:
∂ ARNT Nucleus
∂ t
kb6 = 0.014 zmol
-1.s-1 ku6 = 0.002 s
-1 ARNT (initial) = 6.35E
-3 zmol
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Equation Parameters and initial state variables
A11:
∂CsAcytosol
∂ t
A12:
∂CsAextracellar
∂ t
A13:
∂CsAnuleus
∂ t
A14:
∂CsAwall
∂ t
V cytosol = 1702 µm
3 CLin1 = 99.6 zmol.sec-1 CLout1 = 1483 zmol.sec
-1
V nucleus = 380 µm
3 Kmout1 = 2965 µmol.L
-1 k3 = 0.921
CsAcytosol(initial) = 0 zmol
V max2 = 0.2 sec
-1 Km2 = 2.18E
6 zmol
CsAwall (initial) = 0 zmol
CLin4
= CLin1
CLout 4 =
CLout 1
CsAnucleus(initial) = 0 zmol k1 = 3.55E
-5 sec-1
k 2 = 6.01E
-4 zmol(1-k3).sec-1 Refer to A1 and A2 for the other parameters.
A15:
∂CsA_AhRcytosol
∂ t
CsA_AhRcytosol (initial) = 0 zmol
CLin3 = 10 µm
3.s-1 CLout 3 = 1 µm
3.sec-1
Refer to A1 for the other parameters.
A16:
∂CsA_AhRnucleus
∂ t
CsA_AhRnucleus(initial) = 0 zmol Refer to A2, A11 and A15 for the parameters.
A17:
∂CYPcytosol
∂ t
CYPcytosol(initial) = 34 zmol
k deg24 = 1E-4 s
-1 kTSL23 = 0041 s
-1
A18:
∂ DRECYP
∂ t
kb19 = 1.39 zmol
-2.s-1 ku19 = 0.018 s
-1 n19 = 2
DRE CYP(initial) = 6.35E
-4 zmol
A19:
∂ DREGST
∂ t
kb55 = 13.9 zmol
-2.s-1 ku55 = 0.02 s
-1 n55 = 2
DRE GST (initial) = 6.35E
-4 zmol
A20:
∂ DRE MRP
∂ t
kb64 = 0.26 zmol
-2.s-1 ku64 = 0.02 s
-1 n64 = 1
DRE MRP(initial) = 6.35E
-4 zmol
A21:
∂ DRE Nrf2
∂ t
kb26 = 13.9 zmol
-2.s-1 ku26 = 0.02 s
-1 n26 = 2
DRE Nrf2(initial) = 6.35E
-4 zmol
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Equation Parameters and initial state variables
A22:
∂GCLcytosol
∂ t
kb52 = -
a ku52 = 0.02 s
-1 k deg53 = 3.86E
-5 s-1
GCLcytosol(initial) = 1020 zmol
A23:
∂GCLCcytosol
∂ t
GCLC cytosol (initial) = 2890 zmol
k deg45 = 3.86E
-5 s-1 kTSL44 = 0.0417 s
-1
Refer to A22 for the other parameters.
A24:
∂GCLM cytosol
∂ t
GCLM cytosol(initial) = 612  zmol
k deg51 = 3.86E
-5 s-1 kTSL50 = 0.0417 s
-1
Refer to A22 for the other parameters.
A25:
∂GeneCYPOFF
∂ t
A26:
∂GeneCYPON
∂ t
Gene CYPOFF (initial)
= 6.35E-4 zmol k act20 = 2.5E
-5 s-1 k desact20 = 0.01 s
-1
GeneCYPON (initial)
= 0 zmol kind(NMA)20 = 0.079 zmol
-1.s-1
A27:
∂GeneGCLC OFF
∂ t
28:
∂GeneGCLC ON
∂ t
GeneGCLCOFF (initial)
= 6.35E-4 zmol k act41 = 4E
-4 s-1 k desact 41 = 0.01 s
-1
GeneGCLCON (initial)
= 0 zmol k ind 41 = -
a
A29:
∂GeneGCLM OFF
∂ t
A30:
∂GeneGCLM ON
∂ t
GeneGCLM OFF (initial)
= 6.35E-4 
zmol
k act47 = 4E
-4 s-1 k desact 47 = 0.01 s
-1
Gene GCLM ON (initial)
= 0 zmol kind(NMA)47 = -
a
A31:
∂GeneGSOFF
∂ t
A32:
∂GeneGSON
∂ t
GeneGSOFF (initial)
= 6.35E-4 zmol k act33 = 5E
-4 s-1 k desact33 = 0.01 s
-1
GeneGSON (initial)
= 0 zmol kind(NMA)33
= -a
A33:
∂GeneGST OFF
∂ t
A34:
∂GeneGST ON
∂ t
GeneGST OFF(initial)
= 6.35E-4 zmol k act56 = 1E
-3 s-1 k desact56 = 0.01 s
-1
GeneGST ON (initial)
= 0 zmol kind(NMA)56 = -
a
kind(XAAD)56
= 0.26 zmol-1.s-1
a : parameters estimated.
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Equation Parameters and initial state variables
A35:
∂GeneGPx OFF
∂ t
A36:
∂GeneGPx ON
∂ t
GeneGPxOFF(initial)
= 6.35E-4 zmol k act56b = 1E
-3 s-1 k desact56b = 0.01 s
-1
GeneGPxON (initial)
= 0 zmol kind(NMA)56b = -
a
A37:
∂GeneMRPOFF
∂ t
A38:
∂GeneMRPON
∂ t
GeneMRPOFF(initial)
= 6.35E-4 zmol k act65 = 6.8E
-4 s-1 k desact65 = 0.01 s
-1
GeneMRPON (initial)
= 0 zmol kind(NMA)65 = -
a
kind(XAAD)65
= 1.32 zmol-1.s-1
A39:
∂GeneNrf2OFF
∂ t
A40:
∂GeneNrf2ON
∂ t
Gene Nrf2OFF (initial)
= 6.35E-4 zmol k act27 = 2.5E
-3 s-1 k desact 27 = 0.01 s
-1
Gene Nrf2ON(initial)
= 0 zmol kind(NMA)27 = -
a kind(XAAD)27 = 13 zmol
-1.s-1
A41:
∂GScytosol
∂ t
A42:
∂GSmonocytosol
∂ t
kb38 = 1.2E
-4 zmol-1.s-1 ku38 = 0.02 s
-1 k deg39 = 1.93E
-5 s-1
GScytosol (initial) = 1632 zmol
kTSL36 = 0.0417 s
-1 k deg37 = 3.86E
-5 s-1
GSmono cytosol (initial) = 0 zmol
a : parameters estimated.
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Equation Parameters and initial state variables
A43-A51:
∂ γGC cytosol
∂ t
Glycytosol = 1.7E6 zmol K m173 = 11.2E
5 zmol K m273 = 2.6E
6 zmol
ATPcytosol = 8.5E6 zmol Glucytosol = 1.7E7 zmol
Cyscytosol
= 5.1E5 zmol
vmax73 = -
a K m(Gly)73 = 3E
6 zmol
K m(ATP)73
= 12E4 zmol
K m(Glu)(GCL)72 = 8.2E
5 zmol vmax(GCL)72 = -
a vmax(GCLC)72 = -
a
γGCcytosol(initial) = 2.6E
5 zmol
K m(ATP)(GCLC)72
= 8.5E6 zmol
K is(ATP)(GCLC)72
= 2.2E6 zmol
K m(ATP)(GCL)72 = 14.8E
5 zmol
K ii(ATP)(GCLC)72
= 6.8E5 zmol
K m(Glu)(GCLC)72
= 2.7E6 zmol
K is(ATP)(GCL)72 = 11E
6 zmol K is(Glu)(GCLC)72
= 5.1E5 zmol
K ii(Glu)(GCLC)72
= 14E5 zmol
K ii(ATP)(GCL)72 = 6.6E
6 zmol K m(Cys)(GCL)72 = 3.7E
5 zmol
K m(Cys)(GCLC)72
= 4.6E5 zmol
K is(Glu)(GCL)72 = 14E
5 zmol K ii(Glu)(GCL)72 = 5.3E
6 zmol
A52:
∂GSH cytosol
∂ t
GSH cytosol (initial) = 8.5E
6 zmol vmax74 = 3137 zmol.s
-1 K m74 = 3.4E
7 zmol
K i(GSH)8b = 14.5E
4 zmol K m(GSH)8b = 8.5E
5 zmol vmax8b = -
a
K m(ROS)8b = 8.5E
4 zmol K i(ROS)8b = 14.5E
4 zmol Refer to A51 for the other parameters.
A53:
∂GST cytosol
∂ t
A54:
∂GSTmonocytosol
∂ t
kb61 = 3.4E
-4 zmol.s-1 ku61 = 0.02 s
-1 k deg62 = 1.29E
-5 s-1
GST cytosol(initial) = 250 zmol
kTSL59 = 0.0417 s
-1 k deg60 = 1.29E
-4 s-1
GSTmonocytosol(initial) = 206 zmol
A55:
∂ Keap1cytosol
∂ t
A56:
∂ Keap1ocytosol
∂ t
Keap1cytosol(initial) = 34 zmol
k red 10 = 0.1 s
-1 kox10 = 
 -a
Keap1ocytosol(initial) = 0 zmol
kb14 = 3.4E
-3 zmol.s-1 ku14 = 0.02 s
-1
ku12 = 0.014 s
-1 kb15 = 3.4E
-3 zmol.s-1 ku15 = 0.02 s
-1
ku13 = 1E
-4 s-1
a : parameters estimated.
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Equation Parameters and initial state variables
A57:
∂mRNACYP
∂ t
mRNACYP (initial) = 0.787 zmol
kTSP21 =
 -a k deg22 = 6E
-5 s-1
A58:
∂mRNAGCLC
∂ t
mRNAGCLC (initial) = 3.08 zmol
kTSP42 =
 -a k deg43 = 4.83E
-5 s-1
A59:
∂mRNAGCLM
∂ t
mRNAGCLM (initial) = 1.33 zmol
kTSP48 =
 -a k deg49 = 4.83E
-5 s-1
A60:
∂mRNAGS
∂ t
mRNAGS (initial) = 0.731 zmol
kTSP34 =
 -a k deg35 = 4.83E
-5 s-1
A61:
∂mRNAGST
∂ t
mRNAGST (initial) = 0.731 zmol
kTSP57 =
 -a k deg58 = 4.71E
-5 s-1
A62:
∂mRNAGPx
∂ t
mRNAGPx(initial) = 0.731 zmol
kTSP57b =
 -a k deg58b = 4.71E
-5 s-1
A63:
∂mRNAMRP
∂ t
mRNAMRP(initial) = 6.46 zmol
kTSP66 =
 -a k deg67 = 1.93E
-5 s-1
A64:
∂mRNANrf2
∂ t
mRNANrf2 (initial) = 0.046 zmol
kTSP28 =
 -a k deg29 = 6.43E
-5 s-1
A65:
∂MRPcytosol
∂ t
A66:
∂MRPmonocytosol
∂ t
kb70 = 0.59E
-5 zmol-1.s-1 ku70 = 0.02 s
-1 k deg71 = 7.15E
-6 s-1
MRPcytosol (initial) = 3.4E
3 zmol kTSL68 = 0.0417 s
-1 k deg69 = 1.93E
-5 s-1
MRPmonocytosol (initial) = 3.4E
3 
zmol
A67:
∂MAF nucleus
∂ t
MAF nucleus(initial) = 0.038 zmol
kb18 =
 -a ku18 = 0.02 s
-1
A68:
∂ NMAGCLC
∂ t
NMAGCLC (initial) = 0 zmol Refer to A3 for the parameters.
A69:
∂ NMAGCLM
∂ t
NMAGCLM (initial) = 0 zmol Refer to A4 for the parameters.
A70:
∂ NMAGS
∂ t
NMAGS (initial) = 0 zmol Refer to A5 for the parameters.
A71:
∂ NMAGST
∂ t
NMAGST (initial) = 0 zmol Refer to A6 for the parameters.
A72:
∂ NMAGPx
∂ t
NMAGPx(initial) = 0 zmol Refer to A7 for the parameters.
A73:
∂ NMAMRP
∂ t
NMAMRP(initial) = 0 zmol Refer to A8 for the parameters.
A74:
∂ NMANrf2
∂ t
NMANrf2(initial) = 0 zmol Refer to A9 for the parameters.
a : parameters estimated.
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Equation Parameters and initial state variables
A75:
∂ Nrf2cytosol
∂ t
A76:
∂ Nrf2nucleus
∂ t
Nrf2cytosol (initial) = 0.85 zmol
k deg31 = 1E
-4 s-1 kTSL30 = 0.0417 s
-1
Nrf2nucleus(initial) = 0.038 zmol
CLin16 = 2 µm
3.s-1 CLout 16 = 1 µm
3.s-1
k deg17 = 1E
-4 s-1 Refer to A55, A56, A64 and A67 for the other parameters.
A77:
∂ Nrf2_Keap1cytosol
∂ t
A78:
∂ Nrf2_Keap1ocytosol
∂ t
Nrf2_Keap1cytosol(initial) = 0 zmol
k red11 = 0.1 s
-1
Nrf2_Keap1ocytosol(initial) = 0 zmol
Refer to A55, A56, A62 and A63 for the 
other parameters.
A79 :
∂ Nrf2_MAFnucleus
∂ t
Nrf2_MAF nucleus(initial) = 0 zmol
Refer to A3, A4, A5, A6, A7, A8 and A67 
for the parameters.
A80:
∂ROS cytosol
∂ t
ROS cytosol(initial) = 0 zmol
k f 75 =
 -a k ROS =
 -a
Refer to A52 for the other parameters.
A81:
∂ XAAnucleus
∂ t
XAAnucleus(initial) = 0 zmol
Refer to A9, A17, A18, A19 and A20 for the 
parameters.
A82:
∂ XAADCYP
∂ t
XAADCYP(initial) = 0 zmol Refer to A18 for the parameters.
A83:
∂ XAADGST
∂ t
XAADGST (initial) = 0 zmol Refer to A19 for the parameters.
A84:
∂ XAADMRP
∂ t
XAADMRP(initial) = 0 zmol Refer to A20 for the parameters.
A85:
∂ XAADNrf2
∂ t
XAADNrf2(initial) = 0 zmol Refer to A21 for the parameters.
a : parameters estimated.
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Table S2: Cyclosporine A quantities measured in the extracellular medium (3mL) at low CsA 
concentration exposure (5 µM).
Day Time (in hr)
CsA quantity (in zeptomol)
Replicate 1 Replicate 2 Replicate 3
1
0.5 5.229E-06 5.105E-06 4.667E-06
1 4.667E-06 5.000E-06 3.924E-06
3 5.076E-06 4.695E-06 4.657E-06
6 4.610E-06 4.743E-06 4.343E-06
24 4.686E-06 4.352E-06 3.810E-06
3 24 5.781E-06 5.619E-06 5.210E-06
5 24 6.010E-06 5.771E-06 6.010E-06
7 24 5.076E-06 6.048E-06 5.771E-06
10 24 5.562E-06 5.410E-06 5.181E-06
14
0.5 4.905E-06 5.962E-06 5.219E-06
1 5.333E-06 5.610E-06 5.076E-06
3 5.124E-06 5.314E-06 4.419E-06
6 5.943E-06 5.562E-06 5.162E-06
24 5.238E-06 5.295E-06 4.971E-06
Table S3: Intracellular Cyclosporine A quantities measured. at low CsA concentration exposure (5 
µM).
Day Time (in hr)
CsA quantity (in zeptomol)
Replicate 1 Replicate 2 Replicate 3
1
0.5 1.248E-06 1.181E-06 9.048E-07
1 1.286E-06 1.152E-06 1.114E-06
3 1.390E-06 1.362E-06 1.381E-06
6 1.152E-06 1.248E-06 1.124E-06
24 1.657E-06 1.305E-06 1.171E-06
14
0.5 1.771E-06 2.414E-06 2.086E-06
1 3.271E-06 3.771E-06 3.886E-06
3 2.600E-06 1.886E-06 2.100E-06
6 1.914E-06 2.000E-06 2.543E-06
24 2.043E-06 2.229E-06 2.514E-06
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Table S4: Cyclosporine A quantities measured on plastic at low CsA concentration exposure (5 
µM).
Day Time (in hr)
CsA quantity (in zeptomol)
Replicate 1 Replicate 2 Replicate 3
1
0.5 6.143E-07 7.095E-07 7.286E-07
1 5.762E-07 6.429E-07 6.619E-07
3 5.810E-07 7.667E-07 5.905E-07
6 7.905E-07 8.333E-07 8.095E-07
24 7.714E-07 1.024E-06 1.019E-06
14
0.5 1.010E-06 9.810E-07 8.952E-07
1 9.048E-07 9.905E-07 1.062E-06
3 1.414E-06 1.229E-06 1.462E-06
6 9.238E-07 9.429E-07 8.762E-07
24 7.524E-07 6.333E-07 8.000E-07
Table S5: Cyclosporine A quantities measured in the extracellular medium (3mL) at high CsA 
concentration exposure (15 µM).
Day Time (in hr)
CsA quantity (in zeptomol)
Replicate 1 Replicate 2 Replicate 3
1
0.5 1.888E-05 2.057E-05 1.693E-05
1 1.686E-05 1.733E-05 1.636E-05
3 1.557E-05 1.788E-05 1.674E-05
6 1.555E-05 1.583E-05 1.745E-05
24 1.581E-05 1.660E-05 1.490E-05
3 24 1.664E-05 1.355E-05 1.538E-05
5 24 1.674E-05 1.729E-05 1.605E-05
7 24 1.519E-05 1.612E-05 1.419E-05
10 24 1.652E-05 1.683E-05 1.757E-05
14
0.5 1.917E-05 2.076E-05 1.962E-05
1 2.033E-05 2.007E-05 1.893E-05
3 1.855E-05 1.886E-05 1.833E-05
6 1.836E-05 1.850E-05 1.843E-05
24 1.643E-05 1.612E-05 1.717E-05
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Table S6: Intracellular Cyclosporine A quantities measured at high CsA concentration exposure (15 
µM).
Day Time (in hr)
CsA quantity (in zeptomol)
Replicate 1 Replicate 2 Replicate 3
1
0.5 2.010E-06 1.671E-06 1.619E-07
1 1.852E-06 2.086E-06 1.762E-06
3 2.643E-06 2.500E-06 2.029E-06
6 2.643E-06 2.310E-06 2.548E-06
24 3.714E-05 2.548E-06 3.429E-06
14
0.5 2.222E-05 2.191E-05 1.696E-05
1 2.160E-05 2.303E-05 2.371E-05
3 1.350E-05 1.647E-05 1.548E-05
6 1.603E-05 1.727E-05 2.315E-05
24 1.467E-05 1.356E-05 1.418E-05
Table S7: Cyclosporine A quantities measured on plastic at high CsA concentration exposure (15 
µM).
Day Time (in hr)
CsA quantity (in zeptomol)
Replicate 1 Replicate 2 Replicate 3
1
0.5 4.190E-07 5.238E-07 6.857E-07
1 6.429E-07 8.782E-07 8.857E-07
3 1.533E-07 9.000E-07 9.810E-07
6 7.810E-07 1.143E-06 1.105E-06
24 7.143E-07 1.090E-06 6.381E-07
14
0.5 5.905E-06 4.552E-06 5.000E-06
1 6.390E-06 6.181E-06 7.067E-06
3 8.752E-06 7.905E-06 4.848E-06
6 6.248E-06 4.829E-06 4.448E-06
24 5.086E-06 6.305E-06 5.762E-06
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Table S8: Fold changes measured at low CsA concentration (5 µM).
Species
Day 1 Day 3 Day 14
R1 R2 R3 R1 R2 R3 R1 R2 R3
CYP mRNA 1.115 / / 1.050 / / 0.945 / /
GCLC mRNA 1.043 1.046 / 1.093 1.038 / 1.022 0.995 /
GCLM mRNA 0.999 0.897 / 1.198 1.169 / 1.168 1.316 /
GPx mRNA 0.909 / / 0.930 / / 0.685 / /
GS mRNA 0.951 / / 0.886 / / 0.971 / /
GST mRNA 1.069 1.054 / 0.948 0.981 / 1.081 1.033 /
MRP mRNA 1.086 / / 1.093 / / 1.133 / /
Nrf2 mRNA 0.935 / / 1.329 / / 1.156 / /
GCLM / / / 1.069 / / / / /
GS 0.949 1.010 1.020 0.952 0.964 1.017 0.971 1.003 1.040
GSH 1.092 1.702 0.701 1.416 0.799 1.428 1.945 0.932 1.468
γ-GC 4.602 39.391 2.869 5.192 1.538 2.135 0.542 2.749 0.232
MRP / / / / / / 0.782 / /
Table S9: Fold changes measured at high CsA concentration (15 µM).
Species
Day 1 Day 3 Day 14
R1 R2 R3 R1 R2 R3 R1 R2 R3
CYP mRNA 1.099 / / 1.004 / / 1.211 / /
GCLC mRNA 3.425 1.299 / 1.945 1.211 / 2.478 1.206 /
GCLM mRNA 2.755 4.709 / 2.848 5.154 / 1.769 2.785 /
GS mRNA 0.764 / / 0.728 / / 0.816 / /
GPx mRNA 4.622 / / 2.478 / / 1.476 / /
GST mRNA 1.056 1.077 / 1.010 0.980 / 0.986 0.974 /
MRP mRNA 1.317 / / 1.194 / / 1.081 / /
Nrf2 mRNA 1.133 / / 1.408 / / 1.261 / /
GCLM / / / 1.431 / / / / /
GS 0.971 1.035 0.973 0.955 0.988 1.040 0.943 0.980 1.007
GSH 2.093 1.423 4.528 7.063 8.376 4.216 5.017 2.899 6.975
γ-GC 30.13 181.4 11.38 92.085 525.6 32.53 14.237 39.93 6.953
MRP / / / / / / 0.775 / /
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Figure S1: Transcriptomics (Nrf2 mRNA, CYP mRNA, GS mRNA, GCLC mRNA, GCLM 
mRNA, GPx mRNA, and MRP mRNA) proteomics (GCLM, GS, and MRP), and metabolomics (γ-
GC, and GSH) fold-changes time-course in RPTEC cells during 60 days with repeated low dose (5 
µM) CsA dosing. The blue line indicates the best fitting (maximum posterior probability) model 
prediction. The black lines are predictions made with 49 random parameter sets.
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Figure S2: Transcriptomics (Nrf2 mRNA, CYP mRNA, GS mRNA, GCLC mRNA, GCLM 
mRNA, GPx mRNA, and MRP mRNA) proteomics (GCLM, GS, and MRP), and metabolomics (γ-
GC, and GSH) fold-changes time-course in RPTEC cells during 60 days with repeated high dose 
(15 µM) CsA dosing. The blue line indicates the best fitting (maximum posterior probability) model 
prediction. The black lines are predictions made with 49 random parameter sets.
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